254877-67-3

Basic information

• Product Name: Ataciguat
• Synonyms: 5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide;Ataciguat;HMR 1766
• CAS NO: 254877-67-3
• Molecular Formula: C21H19Cl2N3O6S3
• Molecular Weight: 576.5
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 254877-67-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.613 g/cm³
• Refractive Index: 1.684
• PKA: 5.70±0.50(Predicted)
• CAS DataBase Reference: Ataciguat(CAS DataBase Reference)
• NIST Chemistry Reference: Ataciguat(254877-67-3)
• EPA Substance Registry System: Ataciguat(254877-67-3)

Safety Data

• Hazardous Substances Data: 254877-67-3(Hazardous Substances Data)

Usage

Description

Ataciguat, also known as HMR-1766, is a novel anthranilic acid derivative that belongs to a new structural class of soluble guanylate cyclase (sGC) activators. It is capable of activating the oxidized form of sGC, making it a promising candidate for various therapeutic applications.

Uses

Used in Cardiovascular Applications:
Ataciguat is used as a therapeutic agent for targeting deficient NO/cGMP signaling in hypertension, peripheral artery disease, and coronary artery disease. Its ability to improve endothelial function and reduce platelet activation makes it a potential treatment option for these conditions.
Used in Heart Failure Applications:
Ataciguat is used as a therapeutic agent for treating heart failure. Its sGC activating properties can help improve the overall cardiovascular function and alleviate symptoms associated with heart failure.
Used in Thrombosis Applications:
Ataciguat is used as an antithrombotic agent. Its sGC activating properties can help reduce platelet activation and improve blood flow, making it a potential treatment option for thrombotic disorders.
Used in Erectile Dysfunction Applications:
Ataciguat is used as a therapeutic agent for treating erectile dysfunction. Its ability to improve endothelial function and enhance NO/cGMP signaling can help improve erectile function in patients with this condition.
Used in Experimental Diabetes Applications:
Ataciguat is used as a therapeutic agent for improving endothelial function and reducing platelet activation in experimental diabetes. Its sGC activating properties can help address the vascular complications associated with diabetes.

InChI:InChI=1/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)

Upstream product

• 254877-58-2 2-Amino-5-chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide 
• 2766-74-7 5-chlorothien-2-ylsulfonyl chloride 

Relevant articles and documents

SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body’s production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I